*J. Clin. Med.* **2020**, *9*, 2299

**Table 9.** T-cell targeted drugs in pSS:

co-stimulation

 receptors or ligands inhibition.


**10.** T-cell targeted drugs in pSS: therapies preventing autoantigen presentation.

**Table** 

**anti–IL-7R**α

Phase II


D-VAS ≥ 5/10 or Schirmer < 10 mm

0

 -

 -

 -

 SAEs at 27w

The study is stopped for Portfolio prioritization

[369]
